Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
School of Medical Education, Newcastle University, Newcastle upon Tyne, UK.
Syst Rev. 2018 Apr 18;7(1):61. doi: 10.1186/s13643-018-0721-x.
Three types of central venous access devices (CVADs)-peripherally inserted central catheters (PICCs), skin-tunnelled central catheters (Hickman-type devices), and implantable chest wall Ports (Ports)-are routinely used in the intravenous administration of anti-cancer treatment. These devices avoid the need for peripheral cannulation and allow for home delivery of treatment. Assessments of these devices have tended to focus on medical and economic factors, but there is increased interest in the importance of patient experiences and perspectives in this area. The aim of this systematic review is to synthesise existing research regarding patient experiences of these CVADs to help clinicians guide, prepare, and support patients receiving CVADs for the administration of anti-cancer treatment.
A systematic search of MEDLINE, Embase, and CINAHL research databases will be carried out along with a supplementary reference list search. This review will include quantitative, qualitative, and mixed methods studies published in peer-review journals, reporting some aspect(s) of patient experiences or perspectives regarding the use of PICC, Hickman, or Port CVADs for the administration of anti-cancer drugs. The methodological quality and risk of bias of included papers will be assessed using the Mixed Methods Appraisal Tool (MMAT). Relevant outcome data will be extracted from included studies and analysed using a thematic synthesis approach.
The results section of the review will comprise thematic synthesis of quantitative studies, thematic synthesis of qualitative studies, and the aggregation of the two. Results will aim to offer an account of current understandings of patient experiences and perspective regarding PICC, Hickman-type, and Port devices in the context of anti-cancer treatment. Confidence in cumulative evidence will be assessed using the Confidence in the Evidence from Reviews of Qualitative research (CERQual) approach.
This systematic review protocol is registered with the International Prospective Register of Systematic Reviews (PROSPERO). Registration number: CRD42017065851 . This protocol was prepared using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols checklist (PRISMA-P) (Shamseer et al., BMJ 349: 2015).
三种中心静脉置管（CVAD）设备-外周静脉置入中心静脉导管（PICC）、经皮隧道式中心静脉导管（Hickman 型装置）和可植入胸壁端口（Port）-常用于静脉内给予抗癌治疗。这些设备避免了外周插管的需要，并允许在家中进行治疗。对这些设备的评估往往侧重于医疗和经济因素，但人们对该领域患者体验和观点的重要性越来越感兴趣。本系统评价的目的是综合现有关于患者对这些 CVAD 的体验的研究，以帮助临床医生指导、准备和支持接受 CVAD 接受抗癌治疗的患者。
将对 MEDLINE、Embase 和 CINAHL 研究数据库进行系统搜索，并进行补充参考文献搜索。本综述将包括在同行评议期刊上发表的定量、定性和混合方法研究，报告患者对 PICC、Hickman 或 Port CVAD 用于抗癌药物治疗的某些方面的体验或观点。将使用混合方法评估工具（MMAT）评估纳入论文的方法学质量和偏倚风险。将从纳入的研究中提取相关的结果数据，并使用主题综合方法进行分析。
综述的结果部分将包括定量研究的主题综合、定性研究的主题综合以及两者的综合。结果旨在提供对患者在抗癌治疗背景下对 PICC、Hickman 型和 Port 设备的体验和观点的当前理解的描述。将使用从定性研究中评估证据的置信度（CERQual）方法评估累积证据的置信度。
本系统评价方案在国际前瞻性系统评价注册库（PROSPERO）中注册。注册号：CRD42017065851。本方案使用系统评价和荟萃分析的首选报告项目（PRISMA-P）清单（Shamseer 等人，BMJ 349:2015）编制。
